Europe Postpartum Depression Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Drug, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Europe · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$131.2 MnPlaceholder estimate
Estimate 2025$146.5 Mn19.1% of the global market
Projected 2034$393.3 Mn 168.5%Adds $246.8 Mn over 9 forecast years
CAGR 2025–203411.6%Faster than 71% of 180 Pharmaceuticals markets here
Key players5
Europe is 19.12% of the global market.
Among regions, the largest is North America at $333.6 Mn.
18 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Europe Postpartum Depression Treatment Market Analysis Executive Summary
Postpartum depression treatment helps new mothers with depression after childbirth, using new rapid-acting medicines, antidepressants and therapy.
Key segments of the postpartum Depression Treatment market include treatment (Neuroactive Steroids, Antidepressants and Psychotherapy) and drug (Zuranolone, Brexanolone and SSRIs).
Europe Postpartum Depression Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Europe Postpartum Depression Treatment Market Dynamics
Market Growth Drivers
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the postpartum Depression Treatment market. New products designed around women's biology and digital care are improving access.
Opportunity
Femtech, personalised care and new treatments for under-served conditions open strong growth for the postpartum Depression Treatment market, especially as employers and payers add women's health benefits.
Market Restraints
Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the postpartum Depression Treatment market.
Competitive Landscape for Postpartum Depression Treatment Market in Europe
The postpartum Depression Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Postpartum Depression Treatment Market in Europe
Postpartum Depression Treatment in Europe: rules, payment and research
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).[1] In the countries we cover here, medicines are approved by ANSM (France)[2], BfArM (Germany)[3], AIFA (Italy)[4], Ministry of Health (Russia)[5], AEMPS (Spain)[6] and MHRA (UK)[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[8] ClinicalTrials.gov lists 18 studies on Postpartum Depression Treatment that are recruiting, active or about to start in Europe.[9]
[9]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for postpartum Depression Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Treatment
4.2 By Drug
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Sage Therapeutics
7.2 Biogen
7.3 Pfizer
7.4 Lundbeck
7.5 Eli Lilly and Company
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The postpartum Depression Treatment market can be segmented based on various criteria, including treatment, drug and end user. Here's a breakdown of the market segmentation
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Postpartum Depression Treatment market in Europe?
Placeholder estimate: about $146.5 Mn in 2025, rising to about $393.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Postpartum Depression Treatment market in Europe growing?
Placeholder estimate: about 11.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Postpartum Depression Treatment market report cover?
The report splits the market by treatment (Neuroactive Steroids, Antidepressants, Psychotherapy, Digital Therapy), drug (Zuranolone, Brexanolone, SSRIs) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Postpartum Depression Treatment market?
Key players include Sage Therapeutics, Biogen Inc, Pfizer Inc., Lundbeck and Eli Lilly and Company.
What is driving the Postpartum Depression Treatment market?
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the postpartum Depression Treatment market. New products designed around women's biology and digital care are improving access.
Who regulates Postpartum Depression Treatment in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Postpartum Depression Treatment are running in Europe?
18 studies are recruiting, active or about to start in Europe, counted across the 6 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Postpartum Depression Treatment?
PubMed lists 1,194 papers on Postpartum Depression Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.